Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence – A retrospective single-center study | Zendy

Yanhong Deng | Zendy; Yue Cai | Zendy; Jiayu Lin | Zendy; Jiang Ling | Zendy; Huabin Hu | Zendy

Open Access

Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence – A retrospective single-center study

Author(s) -

Yanhong Deng,

Yue Cai,

Jiayu Lin,

Jiang Ling,

Huabin Hu

Publication year - 2015

Publication title -

gastroenterology report

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.934

H-Index - 26

eISSN - 2304-1412

pISSN - 2052-0034

DOI - 10.1093/gastro/gov051

Subject(s) - medicine , bevacizumab , cetuximab , colorectal cancer , kras , hazard ratio , single center , oncology , metastasis , retrospective cohort study , gastroenterology , cohort , surgery , cancer , chemotherapy , confidence interval

To investigate the overall survival of patients with KRAS wild-type metastatic colorectal cancer (mCRC) after sequentially receiving both bevacizumab and cetuximab during the course of treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog